MEDICAL SCIENCE: GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction

[1]  L. Tavazzi,et al.  GISSI-2: mortality plus extensive left-ventricular damage as "end-point" , 1990, The Lancet.

[2]  J. Hsia,et al.  Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial , 1990 .

[3]  P. Marino,et al.  Effect of streptokinase on left ventricular modeling and function after myocardial infarction: the GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico) Trial. , 1989, Journal of the American College of Cardiology.

[4]  B. Sobel.  Coronary thrombolysis and the new biology. , 1989, Journal of the American College of Cardiology.

[5]  R. Califf,et al.  Tissue plasminogen activator: why the backlash? , 1989, Journal of the American College of Cardiology.

[6]  E. Rapaport.  Thrombolytic agents in acute myocardial infarction. , 1989, The New England journal of medicine.

[7]  H. White,et al.  Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. , 1989, The New England journal of medicine.

[8]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[9]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[10]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[11]  J. Wittes,et al.  Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. , 1988, JAMA.

[12]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[13]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[14]  Sol Sherry,et al.  Thrombolytic Therapy: Current Status , 1988 .

[15]  E. Topol.  Advances in Thrombolytic Therapy for Acute Myocardial Infarction , 1987, Journal of clinical pharmacology.

[16]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[17]  S. Sherry.  Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? , 1987, The American journal of cardiology.

[18]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[19]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .

[20]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[21]  C. G. Blomqvist,et al.  Identification and treatment of low-risk patients after acute myocardial infarction and coronary-artery bypass graft surgery. , 1986, New England Journal of Medicine.

[22]  G S Wagner,et al.  The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system. , 1985, Archives of internal medicine.

[23]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[24]  B. Magnani,et al.  Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction. , 1989, Journal of the American College of Cardiology.

[25]  F. Harrell,et al.  Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. , 1988, Journal of the American College of Cardiology.

[26]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .